Brilinta Use In Pregnancy & Lactation

Women of childbearing potential: Women of childbearing potential should use appropriate contraceptive measures to avoid pregnancy during ticagrelor therapy.
Pregnancy: There are no or limited amount of data from the use of ticagrelor in pregnant women. Studies in animals have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). Ticagrelor is not recommended during pregnancy.
Breast-feeding: Available pharmacodynamic/toxicological data in animals have shown excretion of ticagrelor and its active metabolites in milk (see Pharmacology: Toxicology: Preclinical safety data under Actions). A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ticagrelor therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Fertility: Ticagrelor had no effect on male or female fertility in animals (see Pharmacology: Toxicology: Preclinical safety data under Actions).